Loading...
•
Mar 31, 2025
AIM ImmunoTech Q1 2025 Earnings Report
AIM ImmunoTech reported a narrower net loss and reduced operating expenses in Q1 2025.
Key Takeaways
AIM ImmunoTech's Q1 2025 results showed a significant reduction in net loss and operating expenses, despite a decline in revenue. The company faces potential delisting from the NYSE American due to non-compliance with stockholders' equity requirements.
Net loss decreased to $3.705 million from $5.817 million year-over-year.
Revenue declined to $16,000 from $40,000 in Q1 2024.
Research and development expenses reduced to $1.08 million from $1.951 million.
General and administrative expenses decreased to $2.545 million from $3.815 million.
Forward Guidance
AIM ImmunoTech is actively pursuing strategies to regain compliance with NYSE American listing requirements and secure additional funding to support its operations.
Positive Outlook
- Net loss reduced significantly year-over-year.
- Decreased R&D and G&A expenses indicate improved cost management.
- Company is exploring various funding sources, including equity offerings.
- Engaged in a forbearance agreement providing temporary financial relief.
- Focused on advancing clinical trials for Ampligen.
Challenges Ahead
- Revenue declined compared to the same quarter last year.
- Cash and cash equivalents decreased, raising liquidity concerns.
- Potential delisting from NYSE American due to non-compliance.
- Working capital deficit indicates short-term financial challenges.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...